Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy.
Market Cap | 1.172 Billion | Shares Outstanding | 89.368 Million | Avg 30-day Volume | 729.187 Thousand |
P/E Ratio | 0.0 | Dividend Yield | 0.0 | EPS | -0.41 |
Price to Revenue | 108.1657 | Debt to Equity | 0.1923 | EBITDA | -128.916 Million |
Price to Book Value | 8.3607 | Operating Margin | -1597.9671 | Enterprise Value | 788.55 Million |
Current Ratio | 3.187 | EPS Growth | 0.031 | Quick Ratio | 2.949 |
1 Yr BETA | 0.9031 | 52-week High/Low | 16.85 / 5.92 | Profit Margin | -1867.6851 |
Operating Cash Flow Growth | -49.5894 | Free Cash Flow to Firm (FCFF) TTM | -56.03 Million | Free Cash Flow to Equity (FCFE) TTM | -64.68 Million |
Altman Z-Score | -0.4679 |
Please sign in first
none
none
none
Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
---|---|---|---|---|
|
0 | 2023-09-01 | 3 | |
|
0 | 2023-09-01 | 5 | |
MCHUGH THOMAS S CHIEF FINANCIAL OFFICER |
|
78,500 | 2023-08-14 | 2 |
|
142,025 | 2023-08-11 | 2 | |
DIVIS GREGORY J CHIEF EXECUTIVE OFFICER |
|
159,100 | 2023-08-10 | 2 |
|
0 | 2023-08-01 | 1 | |
|
0 | 2023-08-01 | 2 | |
KIM RICHARD J CHIEF COMMERCIAL OFFICER |
|
0 | 2023-06-05 | 1 |
WILLIAMSON DOUGLAS J CHIEF MEDICAL OFFICER |
|
0 | 2022-02-14 | 0 |
HATTEN SANDRA L SEE REMARKS |
|
59,165 | 2019-12-12 | 0 |
VAUGHN JASON SR. VP, TECHNICAL OPERATIONS |
|
0 | 2019-11-05 | 0 |
|
3,130,573 | 2019-08-07 | 0 | |
GUSKY DAVID P SEE REMARKS |
|
No longer subject to file | 2019-06-30 | 0 |
|
No longer subject to file | 2019-05-09 | 0 | |
DUBOW JORDAN CHIEF MEDICAL OFFICER |
|
0 | 2019-04-29 | 0 |
KANAN MICHAEL F SEE REMARKS |
|
50,538 | 2019-03-07 | 0 |
THOMPSON PHILLANDAS T. SEE REMARKS |
|
113,671 | 2019-03-07 | 0 |
ANDERSON MICHAEL S SEE REMARKS |
|
No longer subject to file | 2018-12-28 | 0 |
|
No longer subject to file | 2018-07-18 | 0 | |
|
No longer subject to file | 2018-07-18 | 0 | |
|
No longer subject to file | 2018-07-18 | 0 | |
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) DEERFIELD PRIVATE DESIGN FUND II, L.P. DEERFIELD SPECIAL SITUATIONS FUND, L.P. |
|
No longer subject to file | 2018-06-25 | 0 |
D'SILVA DHIREN VP IRISH & EUROPEAN OPERATIONS |
|
No longer subject to file | 2018-02-07 | 0 |
|
No longer subject to file | 2017-10-10 | 0 | |
|
No longer subject to file | 2017-10-10 | 0 | |
|
No longer subject to file | 2017-10-10 | 0 | |
|
No longer subject to file | 2017-10-10 | 0 | |
|
No longer subject to file | 2017-10-10 | 0 | |
|
No longer subject to file | 2017-06-28 | 0 |
Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
No current insider transactions |
* -
Code | Definition |
---|---|
A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
C | Conversion of derivative security |
D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
G | Bona fide gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
J | Other acquisition or disposition |
L | Small acquisition under Rule 16a-6 |
M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
O | Exercise of out-of-the-money derivative security |
P | Open market or private purchase of non-derivative or derivative security |
S | Open market or private sale of non-derivative or derivative security |
U | Disposition pursuant to a tender of shares in a change of control transaction |
W | Acquisition or disposition by will or the laws of descent and distribution |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
---|---|---|---|---|
AVADEL PHARMACEUTICALS-ADR AVDL | 2023-12-05 19:15:04 UTC | 4.6202 | 0.6998 | 1500000 |
AVADEL PHARMACEUTICALS-ADR AVDL | 2023-12-05 18:45:04 UTC | 4.6202 | 0.6998 | 1500000 |
AVADEL PHARMACEUTICALS-ADR AVDL | 2023-12-05 18:15:03 UTC | 4.6202 | 0.6998 | 1500000 |
AVADEL PHARMACEUTICALS-ADR AVDL | 2023-12-05 17:45:04 UTC | 4.6202 | 0.6998 | 1500000 |
AVADEL PHARMACEUTICALS-ADR AVDL | 2023-12-05 17:15:04 UTC | 4.6291 | 0.6909 | 1500000 |
AVADEL PHARMACEUTICALS-ADR AVDL | 2023-12-05 16:45:04 UTC | 4.6291 | 0.6909 | 1500000 |
AVADEL PHARMACEUTICALS-ADR AVDL | 2023-12-05 16:15:04 UTC | 4.6291 | 0.6909 | 1500000 |
AVADEL PHARMACEUTICALS-ADR AVDL | 2023-12-05 15:45:04 UTC | 4.6893 | 0.6307 | 1500000 |
AVADEL PHARMACEUTICALS-ADR AVDL | 2023-12-05 15:15:05 UTC | 4.6893 | 0.6307 | 1500000 |
AVADEL PHARMACEUTICALS-ADR AVDL | 2023-12-05 14:45:03 UTC | 4.6819 | 0.6381 | 1500000 |
AVADEL PHARMACEUTICALS-ADR AVDL | 2023-12-05 14:15:04 UTC | 4.6819 | 0.6381 | 1500000 |
AVADEL PHARMACEUTICALS-ADR AVDL | 2023-12-05 13:45:04 UTC | 4.7447 | 0.5753 | 1400000 |
AVADEL PHARMACEUTICALS-ADR AVDL | 2023-12-05 13:15:04 UTC | 4.7447 | 0.5753 | 1400000 |
AVADEL PHARMACEUTICALS-ADR AVDL | 2023-12-05 12:45:05 UTC | 4.7447 | 0.5753 | 1400000 |
AVADEL PHARMACEUTICALS-ADR AVDL | 2023-12-04 22:15:04 UTC | 4.7407 | 0.5793 | 1400000 |
AVADEL PHARMACEUTICALS-ADR AVDL | 2023-12-04 21:45:03 UTC | 4.7407 | 0.5793 | 1400000 |
AVADEL PHARMACEUTICALS-ADR AVDL | 2023-12-04 21:15:03 UTC | 4.7407 | 0.5793 | 1400000 |
AVADEL PHARMACEUTICALS-ADR AVDL | 2023-12-04 20:45:04 UTC | 4.7407 | 0.5793 | 1400000 |
AVADEL PHARMACEUTICALS-ADR AVDL | 2023-12-04 20:15:05 UTC | 4.7407 | 0.5793 | 1400000 |
AVADEL PHARMACEUTICALS-ADR AVDL | 2023-12-04 19:45:03 UTC | 4.7407 | 0.5793 | 1400000 |
Get more info on our International short position coverage here
Holder | Issuer | Net Short Position | Position Date | Origin |
---|---|---|---|---|
Franklin Alternative Strategies Funds- K2 Alternative Strategies Fund | AVDL | -42988.0 shares, $-580767.88 | 2023-08-31 | N-PORT |
Blackstone Alternative Investment Funds- Blackstone Alternative Multi-Strategy Fund | AVDL | -200.0 shares, $-2060.0 | 2023-09-30 | N-PORT |